ArticleIJID regions2025
Effectiveness and safety of tenofovir alafenamide/emtricitabine/bictegravir as a first-line regimen in people with HIV: A retrospective observational study.
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To assess the effectiveness and safety of tenofovir alafenamide/emtricitabine/bictegravir (TAF/FTC/BIC) in patients newly diagnosed with HIV (PWH) in a non-experimental setting. Methods: We conducted a single-center, retrospective observational study that included all newly diagnosed PWH treated with TAF/FTC/BIC at our institution. Virological failure was defined as two consecutive HIV-RNA values of >50 cp/ml after 48 weeks of treatment. Reasons for TAF/FTC/BIC interruption were also collected. The durability of TAF/FTC/BIC was estimated using Kaplan-Meier curves. Results: A total of 236 PWH started TAF/FTC/BIC, with a median follow-up time of 13 months (interquartile range [IQR] 4-27 months). Most PWH were cisgender men (178/236, 75.4%) with a median age at diagnosis of 37 years (IQR 29-48) and a median cluster of differentiation 4 cell counts of 302 cells/mm³ (IQR 117-467). One protocol-defined virological failure was observed, without the development of drug resistance, resulting in an incidence of 3.1 per 1000 person-years of follow-up (95% confidence interval [CI] 0.8-17.3). Six (2.5%) PWH discontinued TAF/FTC/BIC because of toxicity. The estimated durabilities of TAF/FTC/BIC at 12 and 24 months were 84.8% (95% CI 78.6-89.3%) and 75.5% (95% CI 67.6-82.6%), respectively. Conclusions: In our cohort of newly diagnosed PWH treated with TAF/FTC/BIC, the low occurrence of virological failure and discontinuation related to drug toxicities underscores the effectiveness and tolerability of the regimen.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.